Injectable insulin treatment is the most used to treat type 1 diabetes mellitus (DM1) and, in many cases, type 2 diabetes mellitus (DM2); however, factors such as pain of application and inconvenience associated with injections are among those contributing to low adherence to this treatment. This evidence concerns the gene INS and myotonic dystrophy type 2.